|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 June 2002, Vol. 99, No. 11, pp. 3909-3915
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Lymphomas in rheumatoid arthritis patients treated with
methotrexate: a 3-year prospective study in France
Xavier Mariette,
Dominique Cazals-Hatem,
Josiane Warszawki,
Frédéric Liote,
Nathalie Balandraud,
Jean Sibilia, and
the investigators of the
Club Rhumatismes et Inflammation
From the Service de Rhumatologie, Hôpital de
Bicêtre (Assistance publique-Hôpitaux de Paris [AP-HP]),
Le Kremlin Bicêtre, France; Service d'Anatomo-pathologie,
Hôpital Beaujon (AP-HP), Paris, France; Service
d'Epidémiologie, Hôpital de Bicêtre (AP-HP), Le
Kremlin Bicêtre, France; Fédération de Rhumatologie,
Hôpital Lariboisière (AP-HP), Paris, France; Service de
Rhumatologie, Centre Hospitalier Lyon-Sud, Lyon, France; and the
Service de Rhumatologie, Hôpital de Hautepierre, Strasbourg,
France. CRI (Club Rhumatismes et Inflammation): the practitioners who
referred patients are listed in an appendix.
A national prospective study was designed to collect all cases of
lymphoma appearing in patients with rheumatoid arthritis (RA) treated
with methotrexate (MTX) throughout France over a period of 3 years. A
total of 25 cases of lymphoma were recorded, 18 cases of non-Hodgkin
lymphoma (NHL), 3 of which were associated with the presence of
Epstein-Barr virus (EBV) in lymphoma cells, and 7 cases of Hodgkin
disease (HD), 5 of them associated with EBV. Among the 8 patients who
were treated by MTX withdrawal alone, 3 underwent remission, but 2 of
them had a relapse, the third patient with clonal EBV-associated large
granular lymphocytes T-cell NHL remaining alive in complete remission.
The estimated annual incidence rate of NHL in RA patients treated with
MTX was 33.3.10 5 (0-80.5) among men and
16.7.105 (0-33.3) among women. There was no significant
excess with the French population as a comparison: the standardized
mortality ratio (SMR) adjusted for age and sex was 1.07 (0.6-1.7). The
estimated annual incidence rate of HD among men and women was,
respectively, 27.8.105 (0-70.1) and 2.8.105
(0- 9.6). The incidence of HD was significantly increased compared with
the French incidence, with an SMR adjusted for age and sex of 7.4 (3.0-15.3; P < .001). Thus, this 3-year prospective
study indicated that, whereas the risk of NHL was not significantly increased in RA patients treated with MTX, the incidence of HD appeared
to be higher in these patients compared to the French population.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K Visser, W Katchamart, E Loza, J A Martinez-Lopez, C Salliot, J Trudeau, C Bombardier, L Carmona, D van der Heijde, J W J Bijlsma, et al.
Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative
Ann Rheum Dis,
July 1, 2009;
68(7):
1086 - 1093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Askling, E Baecklund, F Granath, P Geborek, M Fored, C Backlin, L Bertilsson, L Coster, L T Jacobsson, S Lindblad, et al.
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
Ann Rheum Dis,
May 1, 2009;
68(5):
648 - 653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Bernatsky, L Joseph, J-F Boivin, C Gordon, M Urowitz, D Gladman, P R Fortin, E Ginzler, S-C Bae, S Barr, et al.
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study
Ann Rheum Dis,
January 1, 2008;
67(1):
74 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Mikuls
The treatment of lymphoma complicating autoimmune disease: two birds with one stone?
Ann. Onc.,
April 1, 2007;
18(4):
615 - 618.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A S Russell, G V Wallenstein, T Li, M C Martin, R Maclean, B Blaisdell, K Gajria, J C Cole, J-C Becker, and P Emery
Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment
Ann Rheum Dis,
February 1, 2007;
66(2):
189 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. M. Symmons
Lymphoma and rheumatoid arthritis--again
Rheumatology,
January 1, 2007;
46(1):
1 - 2.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Biggar, E. S. Jaffe, J. J. Goedert, A. Chaturvedi, R. Pfeiffer, E. A. Engels, and for the HIV/AIDS Cancer Match Study
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS
Blood,
December 1, 2006;
108(12):
3786 - 3791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Smedby, E. Baecklund, and J. Askling
Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics.
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2006;
15(11):
2069 - 2077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, E. A. Engels, R. M. Pfeiffer, G. Gridley, L. Mellemkjaer, J. H. Olsen, K. F. Kerstann, W. Wheeler, K. Hemminki, M. S. Linet, et al.
Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia.
J Natl Cancer Inst,
September 20, 2006;
98(18):
1321 - 1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. LaCasce
Post-transplant lymphoproliferative disorders.
Oncologist,
June 1, 2006;
11(6):
674 - 680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Franklin, M Lunt, D Bunn, D Symmons, and A Silman
Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis
Ann Rheum Dis,
May 1, 2006;
65(5):
617 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Mikuls, J. O. Endo, S. E. Puumala, P. A. Aoun, N. A. Black, J. R. O'Dell, J. A. Stoner, E. C. Boilesen, M. A. Bast, D. A. Bergman, et al.
Prospective Study of Survival Outcomes in Non-Hodgkin's Lymphoma Patients With Rheumatoid Arthritis
J. Clin. Oncol.,
April 1, 2006;
24(10):
1597 - 1602.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Smedby, H. Hjalgrim, J. Askling, E. T. Chang, H. Gregersen, A. Porwit-MacDonald, C. Sundstrom, M. Akerman, M. Melbye, B. Glimelius, et al.
Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype
J Natl Cancer Inst,
January 4, 2006;
98(1):
51 - 60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T. Chang, K. E. Smedby, H. Hjalgrim, C. Schollkopf, A. Porwit-MacDonald, C. Sundstrom, E. Tani, F. d'Amore, M. Melbye, H.-O. Adami, et al.
Medication Use and Risk of Non-Hodgkin's Lymphoma
Am. J. Epidemiol.,
November 15, 2005;
162(10):
965 - 974.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Zintzaras, M. Voulgarelis, and H. M. Moutsopoulos
The Risk of Lymphoma Development in Autoimmune Diseases: A Meta-analysis
Arch Intern Med,
November 14, 2005;
165(20):
2337 - 2344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-h. Feng, J. I. Cohen, S. Fischer, L. Li, M. Sneller, R. Goldbach-Mansky, N. Raab-Traub, H.-J. Delecluse, and S. C. Kenney
Reactivation of Latent Epstein-Barr Virus by Methotrexate: A Potential Contributor to Methotrexate-Associated Lymphomas
J Natl Cancer Inst,
November 17, 2004;
96(22):
1691 - 1702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Yarilin, J. Valiando, and D. N. Posnett
A Mouse Herpesvirus Induces Relapse of Experimental Autoimmune Arthritis by Infection of the Inflammatory Target Tissue
J. Immunol.,
October 15, 2004;
173(8):
5238 - 5246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
